A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
Latest Information Update: 23 Jan 2026
At a glance
- Drugs DNL 628 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Denali Therapeutics Inc
Most Recent Events
- 14 Jan 2026 New trial record